Phio Pharmaceuticals (PHIO) Net Shares Issued and Repurchased (2012 - 2025)
Phio Pharmaceuticals' (PHIO) quarterly Net Shares Issued and Repurchased came in at $5.0 in Q4 2025, down 75.0% on a YoY basis from $20.0 in Q4 2024, and down 75.0% quarter-over-quarter from $20.0 in Q4 2024.
Powered by 
Analysis
Phio Pharmaceuticals (PHIO) Net Shares Issued and Repurchased (2012 - 2025) Analysis & Trends
Phio Pharmaceuticals (PHIO) has reported Net Shares Issued and Repurchased for 14 consecutive years, with $5.0 the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Net Shares Issued and Repurchased fell 75.0% year-over-year to $5.0; the trailing twelve-month figure through Dec 2025 stood at $5.0 (down 75.0% YoY), and the FY2025 full-year result was $5.0, down 75.0% from the prior year.
- Net Shares Issued and Repurchased retreated to $5.0 in Q4 2025 per PHIO's latest filing, from $20.0 in the prior quarter.
- Across five years, Net Shares Issued and Repurchased topped out at $30471.0 in Q4 2022 and bottomed at $5.0 in Q4 2025.
- Historically, Net Shares Issued and Repurchased has averaged $5644.3 across 5 years, with a median of $71.0 in 2021.
- The sharpest annual moves came in 2022 and 2024: Net Shares Issued and Repurchased surged 42816.9% in 2022, then sank 98.98% in 2024.
- Over 5 years, Net Shares Issued and Repurchased stood at $71.0 in 2021, then soared by 42816.9% to $30471.0 in 2022, then plunged by 93.54% to $1969.0 in 2023, then tumbled by 98.98% to $20.0 in 2024, then plunged by 75.0% to $5.0 in 2025.
- According to Business Quant data, Net Shares Issued and Repurchased over the past three periods registered $5.0, $20.0, and $6903.0 for Q4 2025, Q4 2024, and Q1 2024 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Shares Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | - |
| 10 | Phio Pharmaceuticals | 12.08 Mn | 12.08 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 5.00 |
| Dec 31, 2024 | 20.00 |
| Mar 31, 2024 | 6,903.00 |
| Dec 31, 2023 | 1,969.00 |
| Dec 31, 2022 | 30,471.00 |
| Dec 31, 2021 | 71.00 |
| Mar 31, 2021 | 71.00 |
| Dec 31, 2020 | 964.00 |
| Mar 31, 2020 | 364.00 |
| Dec 31, 2019 | 4,754.00 |
| Mar 31, 2019 | 10,000.00 |
| Dec 31, 2018 | 108,250.00 |
| Mar 31, 2018 | 2,000.00 |
| Dec 31, 2017 | 33,038.00 |
| Mar 31, 2017 | 22,638.00 |
| Dec 31, 2016 | 58,569.00 |
| Mar 31, 2016 | 57,566.00 |
| Dec 31, 2015 | 405,164.00 |
| Mar 31, 2015 | 79,000.00 |
| Dec 31, 2014 | 443,995.00 |